Product Name: PAK5 (34-49)
Product Number: PE-01BEF99
Size: 200 µg      Price:58.00
1 mg      $US115.00
5 mg      252.00
Peptide Name: PAK5 (34-49)

Product Use: Services as a blocking peptide for use with the PAK5-ANT rabbit polyclonal antibody (Cat. No.: AB-NK190-2) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CGLPQQWHSLLADTANRP

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2006.2 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: PAK5 pan-specific antibody (Cat. No.: AB-NK190-2)

Scientific Background: PAK5 (also known as PAK7) is a protein-serine/threonine that is a member of the STE group of protein kinases in the STE20 family, and PAKB subfamily. This kinase appears to have a restricted human tissue expression with the highest levels detected in brain, spinal cord and the adrenal gland. PAK5 has been implicated in the regulation of cell morphology, motility and transformation. PAK5 features a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK5 releases monomers from the autoinhibited dimer, enables activation of its phosphotransferase activity. It phosphorylates BAD and prevents apoptosis. It is also involved in microtuble stablization, neurite outgrowth and development. It can destablize F-acting networks and eliminate stress fibres and focal adhesions. PAK5 expression provides a survival signal and could contribute to oncogenesis in this way. PAK5 is overexpressed in epithelial ovarian cancer (EOC), which is faced with an obstacle of paclitaxel resistance (PubMed: 23877225). Its expression was increased with EOC progression through the adenoma to carcinoma sequence, with the highest expression level of PAK5 in invasive and metastatic EOCs. Since PAK5 is correlated to human EOC, and its increased expression promotes EOC progression and induces EOC cell paclitaxel chemoresistance, PAK5 may be a useful target for therapeutic drug development. PAK5 has also been linked with the development of colorectal adenocarcinomas, lung adenocarcinomas, and melanomas (metastatic).